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Introduction
Over the past decade, biologically targeted therapies have
significantly improved the outcome of patients with hemato-
logic malignancies. Rituximab (Rituxan; IDEC-C2B8), a
recombinant humanized monoclonal antibody against CD20,
successfully treats B-cell lymphoma and has recently been
applied in CD20-positive pre-B leukemia.1,2 For T-cell
leukemia/lymphoma, which are relatively resistant to con-
ventional chemotherapy and have a poor prognosis,3 bio-ther-
apeutic targets are being investigated.
Angiogenesis is linked to clinically aggressive tumor sub-
types and advanced-stage disease.4 Vascular endothelial
growth factor-A (VEGF-A) is a main stimulator of tumor-ini-
tiated angiogenesis.5 Increased VEGF-A levels in blood and
tissue are associated with adverse prognosis in leukemia and
lymphoma patients.6,7 In angioimmunoblastic T-cell lym-
phoma (AITL), we have shown that VEGF-A was over-
expressed on endothelial cells, and that this overexpression
was related to tumor infiltration and poor survival. This
demonstrated that endothelial cells, like lymphoma cells, con-
tribute to tumor progression in AITL.8
Tumor progression is a complex process that requires
tumor-endothelial cell interaction.9 Cell adhesion molecules,
such as intracellular cell adhesion molecule-1 (ICAM-1) and
its ligand leukocyte function-associated antigen-1 (LFA-1), are
major mediators of tumor-endothelial crosstalk.10 ICAM-1 is
over-expressed on lymphoma cells,11 and its blockade signifi-
cantly inhibits lymphoma cell aggregation in vitro and lym-
phoma growth in vivo.11,12
Bevacizumab (AvastinTM), a recombinant humanized mon-
oclonal antibody directed against VEGF-A, can reduce tumor
angiogenesis and inhibit tumor growth, either alone or in
combination with chemotherapy.5 It has recently been intro-
duced in hematology and its therapeutic effect has been
demonstrated in acute myeloid leukemia and AITL.13,14 Here
we studied in vivo and in vitro the modalities of its therapeutic
efficiency on T-leukemia/lymphoma. 
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Vascular endothelial growth factor-A, an angiogenesis stimula-
tor expressed on both tumor endothelial and malignant T cells,
is involved in tumor progression in T-leukemia/lymphoma.
Here, we assessed the impact of therapeutic vascular endothe-
lial growth factor-A blockade on tumor-endothelial cell inter-
action and on tumor progression. In a murine xenograft T-
leukemia/lymphoma model, combined bevacizumab (mono-
clonal antibody against vascular endothelial growth factor-A)
with doxorubicin, compared with doxorubicin alone, signifi-
cantly delayed tumor growth and induced prevalence of
tumor cell apoptosis over mitosis. More importantly, the com-
bined treatment induced endothelial cell swelling, microvessel
occlusions, and tumor necrosis. In vitro, co-culture of endothe-
lial cells with T-leukemia/lymphoma cells showed that dox-
orubicin induced expression of intracellular cell adhesion mol-
ecule-1, provided endothelial and malignant T cells were in
direct contact. This was abrogated by bevacizumab treatment
with doxorubicin. Taken together, bevacizumab enhances the
chemotherapeutic effect on T-leukemia/lymphoma cells.
Directly targeting tumor endothelial cells might be a promis-
ing therapeutic strategy to counteract tumor progression in T-
cell malignancies.
Key words: T-cell leukemia/lymphoma, bevacizumab, and
endothelial cells.
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Design and Methods
Cells and reagents
T-leukemia/lymphoma cell lines Jurkat, HUT78, and endothelial
cell line EAhy.926 (American Tissue Culture Collection, Bethesda,
MD, USA) were maintained in RPMI-1640 medium supplemented
with 10% heat-inactivated fetal bovine serum in a humidified
atmosphere of 95% air and 5% CO2 at 37°C. Bevacizumab was
obtained commercially (Hoffmann-la Roche, Basel, Switzerland).
Murine model
Four-week old nude mice (Shanghai Laboratory Animal Center,
China), maintained in pathogen-free conditions, were subcuta-
neously injected with 4×107 Jurkat cells (Day 0). Treatments were
performed on Days 21, 24, 28 and 31 in 3 groups of 10 mice. The
untreated group only received RPMI-1640, the doxorubicin group
received intraperitoneal injection of doxorubicin (6mg/kg), and the
combined treatment group received intraperitoneal injection of
doxorubicin (6mg/kg) and bevacizumab (10mg/kg). All animal
procedures were approved by the Investigational Review Board of
Shanghai Jiao Tong University School of Medicine. Tumor volume
was calculated by the formula: 0.5×a×b2 in centimeters, where ‘a’
is the length and ‘b’ is the width.
For each group, mice were sacrificed at two time points: Day 27
and Day 35. Subcutaneous tumors were dissected and cut into
three parts. These were: (i) immediately snap frozen; (ii) formalde-
hyde-fixed and paraffin-embedded; (iii) glutaraldehyde-fixed and
epoxy-resin-embedded for ultrastructural study.
Pathological analysis
Cell mitosis and apoptosis
Pathological study focused on cell proliferation and cell death on
both tumor and endothelial cells. Mitotic and apoptotic cells were
identified by electron microscopy (Hitachi-7560, Tokyo, Japan), or
using Ki67 antibody (MIB-1, Abcam, Cambridge, UK) and TUNEL
assay8 on tumor sections. Cells were counted on 5 consecutive
microscopic fields by two pathologists who had not been
informed of treatment modalities of the mice. A ProvisAX70
microscope (Olympus, Tokyo, Japan), with wide-field eyepiece
number 26.5 was used. At x400 magnification, this wide-field eye-
piece provided a field size of 0.344mm2. Results were expressed as
the mean number of cells/field at x400 magnification.
Tumor microvessel
Tumor microvessels were analyzed ultrastructurally, focusing
on tumor-endothelial cell relationship. Microvessel density was
assessed on 5 microscopic fields at x400 magnification on tumor
sections immunostained with rat anti-mouse CD31 antibody
(MEC13.3, BDpharmingen, Franklin Lakes, NJ, USA).
Tumor necrosis
Necrosis area was assessed on hematoxylin and eosin stained
tumor sections. Whole slides were scanned and analyzed with a
virtual slide system (Olympus). The ratio between tumor necrosis
area and whole tumor area gave the relative necrosis area
ICAM-1 expression 
ICAM-1 expression of human tumor cells and mouse endothe-
lial cells was detected by immunostaining with goat anti-human
ICAM-1 antibody (polyclonal, R&D Systems, Minneapolis, MN,
USA) and goat anti-mouse ICAM-1 antibody (polyclonal, R&D
Systems) on 5-mm frozen sections, respectively.
Enzyme-linked immunosorbent assay (ELISA)
5×105 endothelial cells were cultured in 6-well plates and grown
in confluence; 1×106 T-leukemia/lymphoma cells were added after
24 h. The T-leukemia/lymphoma and endothelial cells were: (i)
cultured in the same vial; (ii) in Millicell Hanging Cell Culture
System (Millipore Corporation, Billerica, MA, USA) with 1-mm
pore filter only allowing fluid exchange. Cell co-cultures were
treated with doxorubicin (200 ng/mL), or doxorubicin (200 ng/mL)
combined with bevacizumab (100 mg/mL), or untreated. ELISA
was performed in triplicate using ICAM-1 Kit (R&D Systems) on
100 mL supernatant, according to the manufacturer’s instructions.
Flow cytometry
5×105 endothelial cells and 1×106 T-leukemia/lymphoma cells
were co-cultured and treated as described above. Cells were disso-
ciated with EDTA, incubated with Alexa 488-conjugated mouse
anti-human ICAM-1 (84H10, Chemicon, Temecula, CA, USA) and
allophycocyanin-conjugated mouse anti-human CD3 antibodies
(BW264/56, Miltenyi Biotec, Auburn, CA, USA). Flow cytometry
was used to measure fluorescent intensity (BD, Franklin, NJ, USA).
Confocal microscopy
5×105 endothelial cells and 1×106 T-leukemia/lymphoma cells
co-cultured in the same vials were immunolabeled using mouse
anti-human ICAM-1 (84H10, Chemicon) and rabbit anti-human
LFA-1 (polyclonal, Abcam, Cambridge, UK) as primary antibodies,
and FITC-conjugated anti-mouse IgG or TexasRed-conjugated
anti-rabbit IgG as secondary antibodies. Nuclei were counter-
stained with DAPI. Z-stacked images were captured by confocal
microscope (Zeiss-LSM-5, Welwyn Garden City, UK) and ana-
lyzed by IMARIS software (Bitplane, Zurich, Switzerland).
Cell adherence assay
Co-cultured endothelial cells and T-leukemia/lymphoma cells
were treated as described above. Each well was then filled with
culture medium, covered with parafilm, and inverted for 30 min to
remove unattached cells. Remaining adherent lymphoma cells
were counted on five microscopic fields per well, and observed on
inverted phase-contrast microscope (Nikon-TE-300, Japan). All
assays were performed in triplicate.
Statistical analyses
Results were expressed as the mean±SD. Statistical significance
of differences between treatment groups was measured by two-
tailed t-test. P<0.05 was considered to be significant. All statistical
analyses were performed on SAS8.2 (SAS-Institute-Inc., Cary, NC,
USA).
Results 
Bevacizumab targeted tumor cells and inhibited 
tumor growth
To assess the therapeutic efficiency of bevacizumab in
vivo, a xenograft murine model was established. Jurkat and
HUT-78 cells were both tested; only Jurkat cells developed
a tumor at the site of subcutaneous injections. Compared
with doxorubicin alone, combined bevacizumab and dox-
orubicin significantly reduced tumor size, at Day 27 and
Day 35 (P=0.0446 and P=0.0030, respectively, Figure 1A). 
To find how bevacizumab enhanced doxorubicin effect
on T-leukemia/lymphoma cells, mitotic and apoptotic
cells were assessed. In the untreated group, mitotic and
apoptotic cells were respectively 35.3±5.1 and 5.2±1.6 at
Day 27, with few changes at Day 35 (mitotic cells:
31.9±6.8 and apoptotic cells: 6.4±2.7). With doxorubicin,
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mitotic cell numbers were significantly reduced (Day 27:
22.5±4.6 and Day 35: 20.40±4.13, P<0.0001), and apoptot-
ic cell numbers significantly increased (Day 27: 14.2±2.3
and Day 35: 21.4±5.2, P<0.0001). Compared to doxoru-
bicin alone, combined bevacizumab with doxorubicin
induced two important changes at Day 27: (i) a significant
increase in apoptotic cells (21.9±3.9, P<0.0001); (ii) a
prevalence of apoptosis over mitosis. This was linked to a
significant increase of apoptosis, since mitosis cells were
similar between the two groups (Figure 1B).
Bevacizumab targeted endothelial cells 
and induced tumor necrosis
Compared with the untreated group, the microvessel
density remained unchanged in the doxorubicin-treated
group, but was significantly reduced, at Day 27 and Day
35, when bevacizumab was associated with doxorubicin
(P=0.0218 and P=0.0004, respectively, Figure 2A).
Ultrastructural study at Day 27 showed that endothelial
cells were flat with normal nuclei in the untreated group
and in the doxorubicin-treated group. A striking feature in
the combined treatment group was the swelling of
endothelial cells in all microvessels studied. This reduced
the lumen area of microvessels. Complete occlusion of
some microvessels was observed with fibrin clot alone or
fibrin plus tumor cells, some of them apoptotic. At Day
35, endothelial cells remained swelling, and relative tumor
necrosis area was significantly increased in the combined
treatment group swollen, when compared with the dox-
orubicin group (P=0.0103, Figure 2B and C).
Bevacizumab interrupted tumor-endothelial cell 
interaction through ICAM-1 downregulation
Immunostainings of xenograft tumor sections showed
that the numbers of human tumor cells and of murine
microvessels expressing ICAM-1 were significantly
increased with doxorubicin, compared with the untreated
group. Combined bevacizumab with doxorubicin conse-
quently reduced these numbers (Online Supplementary
Figure S1A). 
Since such an effect of bevacizumab had not been pre-
viously reported, we further analyzed ICAM-1 expres-
sion in vitro. When Jurkat and HUT-78 cells were co-cul-
tured with endothelial cells in the same vial, doxorubicin
treatment induced a significant ICAM-1 overexpression,
which was inhibited by addition of bevacizumab. This
effect is absent when using a 1-mm pore filter allowing
cytokine exchange, but not cytoplasmic contact, to sepa-
rate tumor and endothelial cells (Online Supplementary
Figure S1B, left panel). Therefore, ICAM-1 reduction by
Figure 1. Bevacizumab targeted tumor
cells and inhibited tumor growth. (A)
Combined bevacizumab and doxorubicin
significantly reduced tumor size at Day
27 and Day 35, compared with doxoru-
bicin alone. Untreated mice only
received intraperitoneal injection of
RPMI1640. * P<0.05, ** P<0.01. (B)
Transmission electron microscopy (TEM,
Hitachi H7650, bar=10μm) and terminal
deoxytransferase-catalyzed DNA nick-
end labeling (TUNEL, bar=50 mm) analy-
ses showed that combined bevacizumab
with doxorubicin induced a prevalence of
apoptosis over mitosis in tumor cells as
early as Day 27. Mitosis, Apoptosis,
**P<0.01.
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bevacizumab was only observed when direct cytoplasmic
contact occurred. 
Moreover, flow cytometry analysis was carried out to
detect the cell surface ICAM-1 of T-leukemia/lymphoma
cells (CD3+) and endothelial cells (CD3-). Compared with
the untreated group, membrane ICAM-1 of endothelial
cells significantly increased after doxorubicin treatment
(P<0.05), which was also abrogated by addition of beva-
cizumab. The ICAM-1 of T-leukemia/lymphoma cells
had a similar trend (Online Supplementary Figure S1B, right
panel).  
In adhesion assays, combined bevacizumab with dox-
orubicin significantly reduced T-leukemia/lymphoma cell
adhesion to the endothelial monolayer when compared
to doxorubicin alone (Online Supplementary Figure S1C). 
On a confocal microscope, untreated cells were individ-
ualized, expressing LFA-1 but not ICAM-1. Doxorubicin
induced: (i) close association of endothelial with tumor
cells; (ii) strong ICAM-1 expression on endothelial cells.
In particular, ICAM-1 and LFA-1 were co-expressed in
areas where endothelial and tumor cells were in close
contact. Addition of bevacizumab abrogated ICAM-1
expression by endothelial cells, and their close association
with tumor cells (Online Supplementary Figure S1D).
Discussion
Addition of bevacizumab to doxorubicin, in our
xenograft murine model, significantly delayed tumor
growth. First, bevacizumab could induce lymphoma cell
apoptosis, as observed in another xenograft solid tumor
model.15 More importantly, it has a direct effect on tumor
vessels. Systematic ultrastructural analysis of tumor sec-
tions revealed that bevacizumab induced endothelial cell
swelling. This striking morphological change diminished
the area of microvessel lumen and could explain the
decreased tumor blood flow observed with computed
tomography perfusion scan in the bevacizumab-treated
tumor.16 In our model, bevacizumab and doxorubicin also
induced microvessel occlusions, contributed to reduced
microvessel density, and increased tumor necrosis area.
This agrees with clinical data showing that: (i) anti-angio-
genesis reduces the risk of chemotherapy resistance by
targeting endothelial cells rather than tumor cells;17 (ii)
combining bevacizumab with chemotherapy results in
greater anti-tumor effects than either treatment alone.17, 18
Tumor invasion requires interaction between invading
tumor cells and tumor microvessels.19 ICAM-1 plays an
important role in cell adhesion.10 In our model, doxoru-
L. Wang et al.
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Figure 2. Bevacizumab targeted
endothelial cells and induced tumor
necrosis. (A) Combined bevacizumab
with doxorubicin significantly reduced
tumor microvessel density at Day 27
and Day 35. *P<0.05, **P<0.01. (B)
Ultrastructural analysis showed at low
magnification, numerous apoptotic cells
in combined treatment group at Day 27
and in doxorubicin group at Day 35. At
high magnification, microvessels in un-
treated mice had flat endothelium and
circulating intact tumor cells in their
lumen. Microvessels in the doxorubicin
group had flat endothelial cells and
apoptotic bodies in their lumen at Day
35. With the combined treatment,
endothelial cells were swollen with volu-
minous nucleus and cytoplasm, reduc-
ing the lumen. Complete occlusion of
some microvessel lumen was observed
with fibrin clot alone or fibrin plus tumor
cells. Microvessels were indicated by
white broken lines, bar=20 mm. (C)
Compared with doxorubicin alone, com-
bined bevacizumab with doxorubicin sig-
nificantly increased the relative tumor
necrosis area at Day 35. * P<0.05.
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bicin significantly enhanced ICAM-1 expression on both
human tumor cells and murine endothelial cells. In tumor-
endothelial cell co-cultures, we showed that doxorubicin
significantly enhanced ICAM-1 expression only when
direct cytoplasmic contact occurred, mimicking the situa-
tion in vivo. The need for cytoplasmic contact between
tumor and endothelial cells for upregulation of ICAM-1
expression has also been demonstrated in breast cancer
cell lines.20 Using flow cytometry and confocal analyses,
we further confirmed that doxorubicin favored: (i) adhe-
sion of multiple T-lymphoma/leukemia cells to endothe-
lial cells; (ii) ICAM-1 upregulation in endothelial cells; (iii)
concomitant expression of LFA-1 and ICAM-1 in the adhe-
sive tumor and endothelial cells, respectively. The fact that
the addition of bevacizumab, an anti-VEGF antibody,
abrogated this ICAM-1 expression underlines the role of
VEGF in doxorubicin-induced ICAM-1 expression in T-
leukemia/lymphoma. The inter-relationship between dox-
orubicin and VEGF has also been shown in breast, lung,
and melanoma cancer, the addition of doxorubicin
increasing VEGF expression.21 As far as we know, our
study is the first to show that anti-VEGF therapy could
inhibit doxorubicin-induced ICAM-1 expression, leading
to interruption of the ICAM-LFA-1 ligation and a decrease
in T-leukemia/lymphoma-endothelial adhesion. Very
recently, bevacizumab has been reported to block lym-
phocyte adhesion to the endothelium.22
The ICAM-1/LFA-1 pathway also plays a key role in
trans-endothelial migration and extravasation.10
Interrupting ICAM-1-LFA-1 ligation inhibits melanoma
cell extravasation and metastases in a xenografted murine
model.23 By modulating tumor-endothelial interaction
through the ICAM-1/LFA-1 pathway, bevacizumab could
possibly interfere with the metastatic potential of T-
leukemia/lymphoma.
Taken together, bevacizumab enhanced the chemother-
apeutic effect in T- leukemia/lymphoma. Targeting tumor
endothelial cells might be a promising therapeutic strategy
to counteract tumor progression in T-cell malignancies.
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